Skip to main content

Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low263.15
Day High271.36
Open:265.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Press & news

Latest News

More Stories
Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments
BayStreet.ca - Wed Mar 22, 8:09AM CDT
BayStreet.ca
Wed Mar 22, 8:09AM CDT
USA News Group – It’s estimated that 6.7 million Americans over 65 (or more than 1 in 9 seniors) are now living with Alzheimer’s Disease (AD), and the number of diagnoses is on the rise. It’s expected that the burden of...
Should You Buy Biogen Before a Big July Decision?
Motley Fool - Sun Mar 19, 4:30AM CDT
Motley Fool
Sun Mar 19, 4:30AM CDT
Biogen stock has dropped about 40% from its record high.
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
MarketBeat - Tue Mar 14, 12:12PM CDT
MarketBeat
Tue Mar 14, 12:12PM CDT
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,

Latest Articles

Change at the top for Biogen after its controversial Alzheimer’s drug flops
Corporate lobbying ETF seeks to profit from influencing politicians
Biogen cuts price of its Alzheimer’s drug in half after facing criticism for initial cost
Warren Buffett’s Berkshire pares drug holdings, sheds Axalta, Biogen
FDA wants probe into its approval of Alzheimer’s drug from Biogen
Eli Lilly to seek accelerated U.S. FDA approval for its experimental Alzheimer’s drug this year
stars and dogs
The Globe’s stars and dogs for the week
Market movers: Stocks that saw action on Tuesday - and why
U.S. FDA approves Biogen’s Alzheimer’s drug, sending its shares soaring
Market movers: Stocks that saw action on Monday - and why
number cruncher
Twenty U.S. stocks that can withstand market turbulence
Market movers: Stocks that saw action on Wednesday - and why

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.